Pre-Conference Day

PET & SPECT imaging have long helped identify promising radiopharmaceutical targets. Advances in multi-omics, computational biology and quantitative imaging are providing richer insight into target expression, heterogeneity and in vivo behavior over time.

This workshop will explore how these approaches can be combined to distinguish interesting biological targets, and those that simply image well, from those most likely to translate into effective therapeutics.

• Identifying & prioritizing higher-potential targets: Integrating multi-omics and computational biology to assess tumor-to-healthy expression, prevalence, heterogeneity and therapeutic potential before progressing a target
• Looking beyond high tumor uptake: Determining whether a target that looks promising on an initial scan has the biological characteristics required for effective radiopharmaceutical therapy
• Understanding target behavior over time: Using longitudinal PET & SPECT to assess target engagement, retention, washout, clearance and tumor vs healthy-tissue biodistribution
• Building higher-confidence target go/no-go decisions: Combining computational, biological, and human imaging evidence to distinguish targets that simply look promising from those most likely to translate into effective therapeutics

Validating novel targets remains costly and time-consuming, while a wealth of clinical evidence already exists across ADCs, T-cell engagers, bispecifics, and other targeted therapies.

This workshop will explore how to assess targets validated outside radiopharmaceuticals and determine when there is sufficient evidence to justify progression into an RLT program.

• Mining other modalities for targets: What can we learn from ADCs, T-cell engagers, bispecifics, and other targeted therapies to identify clinically validated targets with potential for RPT?
• Determining what translates: Which target characteristics and clinical data are genuinely transferable, and where do RPT requirements diverge across target accessibility, expression density, internalization, heterogeneity, biodistribution, and normal-tissue uptake?
• Building a cross-modality target-selection framework: Define the evidence required to confidently progress a clinically validated target into RPT, identify the additional RPT-specific validation needed and establish